This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medical Key Opinion Leaders In Preeclampsia Join Pluristem's Steering Committee

HAIFA, Israel, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has formed a Preeclampsia Steering Committee to advance its PLacental eXpanded (PLX) cell therapies for the treatment of preeclampsia.

"Preeclampsia is an important indication for our PLX-PAD cells. Based on the dire need for a treatment and the potential of our cell therapy in this indication, we have made it a key priority to enter clinical trials for preeclampsia in the near future," stated Pluristem Chairman and CEO Zami Aberman. "The caliber of medical and scientific thought leaders who have joined our Preeclampsia Steering Committee is a testament to the promise of our PLX cell therapy as a potential treatment for this disease."

Preeclampsia Steering Committee Member, Dr. Sibai, who was a moderator on the preeclampsia scientific forum, "Debate and Consensus: Preeclampsia Biomarkers in Clinical Practice, Are we ready?" at the Society for Maternal Fetal Medicine in New Orleans on Feb 5, 2014, commented, "For almost a thousand years, physicians have had no therapy to offer women with preeclampsia. A safe and effective therapy is needed to treat these women and prolong gestation. Pluristem's PLX cells are a unique potential therapy because they originate from the placenta, which plays a key role in preeclampsia."
Pluristem ' s Preeclampsia Steering Committee:
Prof. James M. Roberts, M.D.
University of Pittsburgh
Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
Professor of Epidemiology, Senior Scientist, Magee-Women's Research Institute
Prof. George R. Saade, M.D.
University of Texas Medical Branch
Professor, Division Chief Obstetrics & Gynecology
Prof. Baha M. Sibai, M.D.
University of Texas Medical School
Visiting Professor
Dr. David Williams, PhD FRCP
University College London
Honorary Senior Lecturer, Maternal & Fetal Medicine, Institute for Women's Health, Faculty of Population Health Sciences
Prof. Simcha Yagel, M.D.
Hadassah Medical Center, Israel
Head Division of Obstetrics and Gynecology at Hadassah Medical Center
Head of the Israeli Association of Placental Study 

The Preeclampsia Steering Committee will guide Pluristem's preeclampsia program including advising on various stages of clinical trials, from the design of the study protocol through processing patient feedback up to the final study report. Committee members have vast knowledge of preeclampsia and a commitment to finding a treatment.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,861.11 +70.92 0.42%
S&P 500 1,987.31 +7.39 0.37%
NASDAQ 4,762.3190 +13.9580 0.29%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs